P-63 Subcutaneous levetiracetam for the management of seizures at the end of life

Sutherland, Anna; Curtin, John J.; Bradley, Victoria; Presswood, Maggie; Bush, Olivia; Hedges, Victoria; Naessens, Katrien

doi:10.1136/bmjspcare-2017-00133.63

Poster Presentations 2017

DOI: 10.1136/bmjspcare-2017-00133.63

|View full text |Cite

P-63 Subcutaneous levetiracetam for the management of seizures at the end of life

Anna Sutherland¹,

John J. Curtin

Victoria Bradley

et al.

Abstract: only 2/10 had 'protected' SPA time (an important factor in maintaining adequate Continuing Personal Development). This small pilot study is to be extended across the region.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2018

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Continuous subcutaneous levetiracetam in end-of-life care

Furtado¹,

Gonçalves

et al. 2018

BMJ Case Reports

View full text Add to dashboard Cite

Seizures constitute a determining aspect in quality of life and are frequently challenging in palliative care—a field where treatment has yet to be standardised. Levetiracetam—a new generation anticonvulsant—has proved efficacy both through oral, as well as intravenous administration in the general population. This case reports on the use of continuous subcutaneous levetiracetam to effectively control seizures in a terminally ill patient without patent oral route.

show abstract

Continuous subcutaneous levetiracetam in end-of-life care

Furtado¹,

Gonçalves

et al. 2018

BMJ Case Reports

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

P-63 Subcutaneous levetiracetam for the management of seizures at the end of life

Abstract: only 2/10 had 'protected' SPA time (an important factor in maintaining adequate Continuing Personal Development). This small pilot study is to be extended across the region.

Cited by 1 publication

References 0 publications

Continuous subcutaneous levetiracetam in end-of-life care

Continuous subcutaneous levetiracetam in end-of-life care

Contact Info

Product

Resources

About